What are the recommended dosing and routes of administration for Isovue (iopamidol) contrast in adults and pediatric patients?

ISOVUE Dosing and Route of Administration

ISOVUE (iopamidol) is administered intravenously with weight-based and procedure-specific dosing: for adults, doses range from 2-50 mL per injection depending on the vascular territory (cerebral, peripheral, coronary), with maximum cumulative doses of 90-250 mL; for pediatric patients, CT imaging requires 1.0-3.0 mL/kg (maximum 30 grams iodine), while angiocardiography uses age-stratified dosing from 10-50 mL per injection. 1

Route of Administration

• Intravenous (IV) only for ISOVUE-300 and ISOVUE-370 1
• ISOVUE-300 and ISOVUE-370 are NOT for intrathecal use 1
• Solutions should be warmed to body temperature before injection 1
• Sterile technique is mandatory for all intravascular injections 1

Adult Dosing by Indication

Cerebral Arteriography

• Use ISOVUE-300 (300 mg iodine/mL)
• Single injection: 8-12 mL via carotid puncture or transfemoral catheterization
• Maximum cumulative dose: 90 mL 1

Peripheral Arteriography

• Use ISOVUE-300
• Femoral/subclavian artery injection: 5-40 mL
• Aortic injection for distal runoff: 25-50 mL
• Maximum cumulative dose: 250 mL 1

Peripheral Venography (Phlebography)

• Use ISOVUE-300
• Dose per lower extremity: 15-100 mL
• Maximum combined total: 230 mL 1

Selective Visceral Arteriography and Aortography

• Use ISOVUE-370 (370 mg iodine/mL)
• Large vessels (aorta, celiac artery): up to 50 mL
• Renal arteries: up to 10 mL
• Maximum cumulative dose: 225 mL 1

Coronary Arteriography and Ventriculography

• Use ISOVUE-370
• Selective coronary injections: 2-10 mL
• Ventriculography or aortic root injection: 25-50 mL
• Maximum cumulative dose: 200 mL
• EKG monitoring is essential 1

Computed Tomography (CT)

CT of the Head:

• Use ISOVUE-300
• Dose: 100-200 mL IV
• Imaging performed immediately after administration 1

CT of the Body:

• Use ISOVUE-300 (or equivalent ISOVUE-370 based on iodine content)
• Dose: 100-200 mL via rapid IV infusion or bolus
• Maximum total dose: 60 grams iodine 1

Pediatric Dosing

Pediatric Angiocardiography

• Use ISOVUE-370

Single Injection Doses:

• <2 years: 10-15 mL
• 2-9 years: 15-30 mL
• 10-18 years: 20-50 mL

Cumulative Injection Limits:

• <2 years: 40 mL
• 2-4 years: 50 mL
• 5-9 years: 100 mL
• 10-18 years: 125 mL 1

Pediatric CT Imaging

• Use ISOVUE-300
• Dose: 1.0-3.0 mL/kg
• Maximum total dose: 30 grams iodine 1

Research supports this weight-based approach, with studies demonstrating safety at doses of 1.69 mL/kg (range 1.22-2.42 mL/kg) in children with reflux or obstructive nephropathy 2.

Critical Safety Considerations

Pre-Administration Requirements

• Patients must be well hydrated before and after ISOVUE administration 1
• Screen for renal impairment in high-risk patients (diabetes, hypertension, renal disease, age >70) 3, 4
• Assess estimated glomerular filtration rate (eGFR); high nephrotoxicity risk when creatinine >1.5 mg/dL or eGFR <60 mL/min 3

Metformin Management

If administering IV contrast:

• Discontinue metformin at time of procedure
• Withhold for 48 hours post-procedure
• Reinstitute only after confirming normal renal function in high-risk patients 3

Contrast-Induced AKI Prevention

For patients at increased risk, the KDIGO guidelines recommend 4:

• IV volume expansion with isotonic sodium chloride or sodium bicarbonate (1A recommendation)
• Use lowest possible contrast dose (Not Graded)
• Avoid oral fluids alone (1C recommendation)

ISOVUE (iopamidol) is a low-osmolar contrast medium, which is preferred over high-osmolar agents in patients at increased risk of contrast-induced AKI 4. Studies comparing iopamidol with iso-osmolar iodixanol show equivalent safety profiles 5, though one trial found lower creatinine increases with iopamidol versus iodixanol in diabetic patients (5.1% vs 13%) 5.

Dosing Principles

• Use the lowest dose necessary for adequate visualization 1
• Individualize based on age, body size, vessel size, blood flow rate, pathology, and equipment 1
• Inspect solutions for particulate matter and discoloration; discard if crystallization present 1
• No other pharmaceuticals should be admixed with ISOVUE due to incompatibility 1

Adverse Reaction Profile

Real-world surveillance data from 137,473 patients showed overall AAR incidence of 0.31% with Isovue-370, including 0.16% mild, 0.06% moderate, and 0.01% severe reactions 6. Female patients, emergency patients, elderly (50-60 years), and those undergoing coronary CTA had higher AAR risk 6.